(Q38018504)

27 August 2017

Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease (English)

1 reference

27 August 2017

0 references

1 reference

4

1 reference

27 August 2017

Lezanne Ooi

1

0 references

Perminder Sachdev

object named as

Perminder Sachdev

6

0 references

Anne Poljak

object named as

Anne Poljak

3

0 references

author name string

Kuldip Sidhu

2

1 reference

PubMed ID

22695755

27 August 2017

Michael D O'Connor

5

1 reference

PubMed ID

22695755

27 August 2017

Gerald Münch

7

1 reference

27 August 2017

13 June 2012

1 reference

Journal of Neural Transmission

27 August 2017

1 reference

27 August 2017

120

1 reference

27 August 2017

1

1 reference

27 August 2017

103-111

1 reference

https://scigraph.springernature.com/pub.10.1007/s00702-012-0839-2

27 August 2017

0 references

cites work

Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Synaptic degeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Selective cell death of hyperploid neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

The controlled generation of functional basal forebrain cholinergic neurons from human embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-beta formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Metal complexing agents as therapies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Role for glyoxalase I in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Human induced pluripotent stem cells derived under feeder-free conditions display unique cell cycle and DNA replication gene profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Vaccine development for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Introduction to induced pluripotent stem cells: advancing the potential for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Activated astroglia during chronic inflammation in Alzheimer's disease--do they neglect their neurosupportive roles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Tau protein in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Molecular dissection of the paired helical filament

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Dissecting toxicity of tau and beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Lipoic acid as a novel treatment for Alzheimer's disease and related dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Neuroprotective therapies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Differential effects of "Advanced glycation endproducts" and beta-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Potential neurotoxic inflammatory responses to Abeta vaccination in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

DNA methylation dynamics in human induced pluripotent stem cells over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Functional assays for human embryonic stem cell pluripotency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Generation of germline-competent induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Chromatin crosstalk in development and disease: lessons from REST

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Disease-specific induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Lessons from the AN 1792 Alzheimer vaccine: lest we forget.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

The cholinergic system in aging and neuronal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

New approaches for the generation of induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Why are drug trials in Alzheimer's disease failing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

The development of amyloid beta protein deposits in the aged brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

[New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs)].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Early cell fate decisions of human embryonic stem cells and mouse epiblast stem cells are controlled by the same signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Direct conversion of fibroblasts to functional neurons by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Functional modules distinguish human induced pluripotent stem cells from embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Interleukins, inflammation, and mechanisms of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Modeling familial Alzheimer's disease with induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Induced pluripotent stem cell lines derived from human somatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Neural Precursors from Canine Skin: A New Direction for Testing Autologous Cell Replacement in the Brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0839-2

Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells

21 January 2018

1 reference

12 December 2020

Induced pluripotent stem cells--opportunities for disease modelling and drug discovery

1 reference

12 December 2020

Stem cells: The growing pains of pluripotency

1 reference

12 December 2020

Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists.

1 reference

12 December 2020

Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation

1 reference

12 December 2020

Parkinson disease: Induced pluripotent stem cells-a new in vitro model to investigate α-synuclein dysfunction in Parkinson disease

1 reference

12 December 2020

Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide

1 reference

12 December 2020

A human stem cell model of early Alzheimer's disease pathology in Down syndrome

1 reference

12 December 2020

Advanced glycation endproducts in ageing and Alzheimer's disease

1 reference

12 December 2020

Free radicals in Alzheimer's disease.

1 reference

12 December 2020

Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts

1 reference

12 December 2020

10.1007/S00702-012-0839-2

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22695755